Moffitt Presentation at SITC 2022

Time

Location

Type

Abstract Title

Presenter

11:55 a.m.

258ABC

Oral

666: Phase 2, Single Arm Study of CG0070 Combined with Pembrolizumab in Patients with Non Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG)

Roger Li

12:33 p.m.

258ABC

Oral

789: Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: Pooled analysis of consecutive cohorts (C-144-01 study)

Amod Sarnaik

5:04 p.m.

253ABC

Oral

Radiomics Response to Immunotherapy

Jaileene Perez-Morales

6:45 p.m.

210ABC

Oral

Multifaceted Anti-tumor Effects of Intra-tumoral Tertiary Lymphoid Structures are Driven by Tfh Cells

Jose Conejo-Garcia

11:40 a.m.–1:10 p.m.

7:30–9:00 p.m.

Hall C

Poster

609: Nitric oxide dependent improved relapse free survival to ipilimumab therapy in melanoma patients

Joseph Markowitz

11:40 a.m.–1:10 p.m.

7:30–9:00 p.m.

Hall C

Poster

617: Neoadjuvant intratumoral TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab; preliminary clinical and biomarker data in patients with operable locoregionally advanced melanoma

Ahmad Tarhini

11:40 a.m.–1:10 p.m.

7:30–9:00 p.m.

Hall C

Poster

645: Phase I Study of Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine and Pepinemab/Trastuzumab in Patients with Metastatic HER2-Positive Breast Cancer (MBC)

Heather Han

11:40 a.m.–1:10 p.m.

7:30–9:00 p.m.

Hall C

Poster

681: A phase 1 study of CUE-101, a novel HPV16 E7-pHLA-IL2-Fc fusion protein, as monotherapy and in combination with pembrolizumab in patients with recurrent/metastatic HPV16+ head and neck cancer

Christine Chung

11:40 a.m.–1:10 p.m.

7:30–9:00 p.m.

Hall C

Poster

1147: Differences in co-expression of T cell co-inhibitory and co-stimulatory molecules with PD1 across different human cancers

Ahmad Tarhini

11:40 a.m.–1:10 p.m.

7:30–9:00 p.m.

Hall C

Poster

1279: A novel graphical deep neural network learning approach utilizing molecular data for optimizing patient selection for treatment with immune checkpoint inhibitors: An ORIEN pan-cancer study

Issam El-Naqa

Time

Location

Type

Abstract Title

Presenter

5:50 p.m.

Hall B2

Poster

944: Targeting of Notch ligand Jagged2 in lung cancer cells drives anti-tumor immunity via Notch-induced functional reprogramming of tumor-associated macrophages

Darwin Chang

11:55 a.m.–1:25 p.m.

7:00–8:30 p.m.

Hall C

Poster

54: Prognostic value of T cell immunoscore estimated from transcriptomic data in patients with advanced malignancies treated with immune checkpoint inhibitors

Ahmad Tarhini

11:55 a.m.–1:25 p.m.

7:00–8:30 p.m.

Hall C

Poster

56: High pretreatment DHEA level is associated with shorter overall survival in newly diagnosed metastatic non-small cell lung cancer patients receiving immune checkpoint inhibitors

Yumeng Zhang

11:55 a.m.–1:25 p.m.

7:00–8:30 p.m.

Hall C

Poster

248: Intrathecal Delivery of Dendritic Cell Vaccine Eradicates Tumor Growth and Protects Against Leptomeningeal Disease Re-inoculation in Immunocompetent HER2+ and Triple Negative Breast Cancer LMD Xenograft Models

Vincent Law

11:55 a.m.–1:25 p.m.

7:00–8:30 p.m.

Hall C

Poster

912: Epigenetic remodeling enhances therapeutic responses to STING agonism in vivo

Rana Falahat

11:55 a.m.–1:25 p.m.

7:00–8:30 p.m.

Hall C

Poster

1132: Impact of intralesional oncolytic viral therapy targeting in situ activation of CD40 and type 1 interferon signaling pathways on the TME and systemic T cell immunity in murine models and cancer patients

Andreas Saltos